Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease

Glucose-lowering interventions in Type 2 diabetes mellitus have demonstrated reductions in microvascular complications and modest reductions in macrovascular complications. However, the degree to which targeting different HbA1c reductions might reduce risk is unclear.Participant-level data for Trial...

Full description

Bibliographic Details
Main Authors: Mostafa, SA, Coleman, RL, Agbaje, OF, Gray, AM, Holman, RR, Bethel, MA
Format: Journal article
Language:English
Published: Wiley 2017